Surfkast, response rates continue to improve with those percentages going higher as Amtagvi moves to earlier lines of treatment. The trial rates were exceedingly good given the health and condition of the earliest trial patients who had failed on everything else and had no other options at the time. Now we have Amtagvi being recommended for earlier lines which has been demonstrating better response rates and a possibility that Amtagvi will be a possible first line treatment in specific patient types.
Good news keeps rolling in. ASCO will likely offer even more support and data for earlier treatment recommendations.
News 
Market Data 
Discover 
AI
